Beam Therapeutics Newsroom

Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)

TipRanksMay 11 09:55

Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones

TipRanksMay 10 13:25

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)

TipRanksMay 9 20:35

Beam Therapeutics Analyst Ratings

BenzingaMay 9 02:05

Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33

BenzingaMay 9 02:05

Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Travere Therapeutics (TVTX) and Oscar Health (OSCR)

TipRanksMay 8 17:25

Wedbush: Reiterates the Beam Therapeutics (BEAM.US) rating and adjusted from better than market to better than market rating, with a target price of $57.00.

Zhitong FinanceApr 24 00:40

Beam Therapeutics Analyst Ratings

BenzingaApr 24 00:35

Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments

TipRanksApr 3 07:30

Beam Therapeutics Analyst Ratings

BenzingaMar 27 22:15

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)

TipRanksMar 26 18:25

Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating

MT NewswiresFeb 29 00:27

Barclays: Maintaining a wait-and-see rating for Beam Therapeutics (BEAM.US) shares, and the target price was adjusted from $26.00 to $42.00.

Zhitong FinanceFeb 29 00:10

Beam Therapeutics Analyst Ratings

BenzingaFeb 28 22:56

RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk

MT NewswiresFeb 28 20:49

Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)

TipRanksFeb 28 19:32

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)

TipRanksFeb 28 19:00

Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating

MT NewswiresFeb 28 02:15

JP Morgan Upgrades Beam to Overweight, Cites AATD Therapy Potential

Seeking AlphaJan 30 03:48

JP Morgan Upgrades Beam Therapeutics to Overweight, Raises Price Target to $40

BenzingaJan 29 18:43